TY - JOUR
T1 - Infection of hepatitis A virus in Japanese haemophiliacs
AU - Hayashi, K.
AU - Fukuda, Y.
AU - Nakano, I.
AU - Katano, Y.
AU - Nagano, K.
AU - Yokozaki, S.
AU - Hayakawa, T.
AU - Toyoda, H.
AU - Takamatsu, J.
PY - 2001
Y1 - 2001
N2 - Objectives: Outbreaks of hepatitis A virus (HAV) infection in haemophiliacs have been reported from many countries. The aim of this study was to determine the prevalence of hepatitis A virus antibody (HAVAb) in Japanese haemophiliacs. Methods: Sixty-seven male haemophiliacs were recruited for this study of HAV infection. We also compared the rate of HAV infection with that of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis G virus (HGV). Results: Fifteen of 67 haemophiliacs (22.4%) were positive for HAVAb. Prevalence of HAVAb was significantly higher in haemophiliacs than in Japanese normal subjects previously reported (P=0.0001). Age, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and prevalence of HIV, HCV, and HGV were not statistically different between HAVAb positive and HAVAb negative haemophiliacs. We suggest that the use of clotting factor concentrates is closely associated with HAV infection, but HAV infection does not have an effect on clinical course. Conclusions: Administration of clotting factor concentrates may increase risk of HAV infection in haemophiliacs.
AB - Objectives: Outbreaks of hepatitis A virus (HAV) infection in haemophiliacs have been reported from many countries. The aim of this study was to determine the prevalence of hepatitis A virus antibody (HAVAb) in Japanese haemophiliacs. Methods: Sixty-seven male haemophiliacs were recruited for this study of HAV infection. We also compared the rate of HAV infection with that of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis G virus (HGV). Results: Fifteen of 67 haemophiliacs (22.4%) were positive for HAVAb. Prevalence of HAVAb was significantly higher in haemophiliacs than in Japanese normal subjects previously reported (P=0.0001). Age, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and prevalence of HIV, HCV, and HGV were not statistically different between HAVAb positive and HAVAb negative haemophiliacs. We suggest that the use of clotting factor concentrates is closely associated with HAV infection, but HAV infection does not have an effect on clinical course. Conclusions: Administration of clotting factor concentrates may increase risk of HAV infection in haemophiliacs.
UR - http://www.scopus.com/inward/record.url?scp=0034930608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034930608&partnerID=8YFLogxK
U2 - 10.1053/jinf.2000.0781
DO - 10.1053/jinf.2000.0781
M3 - Article
C2 - 11243755
AN - SCOPUS:0034930608
SN - 0163-4453
VL - 42
SP - 57
EP - 60
JO - Journal of Infection
JF - Journal of Infection
IS - 1
ER -